Skip to main content
Premium Trial:

Request an Annual Quote

Castle Biosciences Acquires Myriad Genetics' MyPath Melanoma Test, Lab for $32.5M

NEW YORK – Castle Biosciences on Tuesday said it will acquire the Myriad myPath Melanoma laboratory and test from Myriad Genetics for $32.5 million in cash and cash equivalents.

The CLIA-certified laboratory in Utah performs Myriad's 23-gene expression profile myPath Melanoma test, which is designed to provide additional information following histopathology to help doctors distinguish if patients' skin lesions are benign or cancerous.

The acquisition will bolster Castle's pipeline of tests for dermatologic cancers. The Texas-based company currently markets DecisionDx DiffDx-Melanoma, a 35-gene expression profile test for diagnosing challenging melanocytic lesions.

"We believe this acquisition will add incremental value to both myPath Melanoma and DiffDx-Melanoma by leveraging the strengths of these two distinct, validated tests," Derek Maetzold, Castle's CEO and president, said in a statement, noting that it will enable more patients to more frequently receive actionable results.

Myriad will continue to offer myPath until the transaction closes in four weeks. The company had previously said that it would sell several assets, including myPath Melanoma, its RBM pharmaceutical contract research business, and the Vectra DA rheumatoid arthritis test, as part of a plan to put the company back on a path to financial recovery and refocus on core testing markets, such as hereditary cancer and mental health pharmacogenomics.

"We are pleased to sign an agreement with Castle Biosciences that meets our objective of ensuring patients continue to have access to this important test and providing value for our shareholders," Paul Diaz, CEO and president of Myriad, said in a statement. "The divestiture of Myriad myPath Melanoma will allow Myriad to focus on its core businesses in women's health, oncology, and mental health and provide growth capital for future investment."

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.